Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Al.3O4S.H2O |
| Molecular Weight | 360.166 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
InChI
InChIKey=BUACSMWVFUNQET-UHFFFAOYSA-H
InChI=1S/2Al.3H2O4S.H2O/c;;3*1-5(2,3)4;/h;;3*(H2,1,2,3,4);1H2/q2*+3;;;;/p-6
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.google.com/patents/US2824042 | https://www.ncbi.nlm.nih.gov/pubmed/22718290 | https://www.ncbi.nlm.nih.gov/pubmed/15516810 | https://www.ncbi.nlm.nih.gov/pubmed/10211213 | https://www.drugs.com/monograph/aluminum-acetate.html
Curator's Comment: Description was created based on several sources, including
https://www.google.com/patents/US2824042 | https://www.ncbi.nlm.nih.gov/pubmed/22718290 | https://www.ncbi.nlm.nih.gov/pubmed/15516810 | https://www.ncbi.nlm.nih.gov/pubmed/10211213 | https://www.drugs.com/monograph/aluminum-acetate.html
Burow invented an astringent antiseptic solution of aluminium acetate in water to relieve the itching and inflammation of minor skin irritations. At present the oflicial U. S. P. procedure to made Burow's solution involves the reaction of aluminum sulfate, calcium carbonate and acetic acid to form aluminum sub-acetate, also termed basic aluminum acetate.
The solution is available as an over-the-counter drug for topical administration, with brand names including Domeboro. Burow's solution has been shown to be effective against chronic suppurative otitis media and otitis externa. It is active against bacteria resulting in damage to the cell wall.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364031 |
|||
Target ID: GO:0042310 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DOMEBORO Approved UseTemporarily relieves minor skin irritations due to:
– Poison ivy | – Poison oak
– Poison sumac | – Insect bites
– Athlete’s foot | – Rashes caused by soaps, detergents, cosmetics, or jewelry |
|||
| Curative | DOMEBORO Approved UseThis medication is used to treat an outer ear infection (external otitis). This product contains acetic acid/aluminum acetate, a combination that stops the growth of bacteria and fungus. Treating the infection reduces pain and swelling in the ear. Wetness in the ear canal can help bacteria and fungus to grow. This medication also causes drying of the ear canal, helping to cure the infection. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The ineffectiveness of aluminum subacetate in rheumatoid arthritis. | 1948 Apr 8 |
|
| Aluminum fluoride induces phosphatidylinositol turnover, elevation of cytoplasmic free calcium, and phosphorylation of the T cell antigen receptor in murine T cells. | 1987 Nov 15 |
|
| Cardiovascular manifestations of aluminium phosphide intoxication. | 1989 Sep |
|
| Plasma renin activity in shock due to aluminium phosphide poisoning. | 1990 Jun |
|
| Hypermagnesemia following aluminum phosphide poisoning. | 1991 Feb |
|
| Requirement for intramolecular domain interaction in activation of G protein alpha subunit by aluminum fluoride and GDP but not by GTP gamma S. | 1994 Nov 25 |
|
| Manipulation of B cell antigen receptor tyrosine phosphorylation using aluminum fluoride and sodium orthovanadate. | 1995 Nov |
|
| Effect of aluminum phosphide on blood glucose level. | 1999 Feb |
|
| Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study. | 1999 May |
|
| Intravascular hemolysis in aluminium phosphide poisoning. | 1999 Sep |
|
| Effect of N-acetylcysteine and L-NAME on aluminium phosphide induced cardiovascular toxicity in rats. | 2001 Apr |
|
| Cholinesterase inhibition by aluminium phosphide poisoning in rats and effects of atropine and pralidoxime chloride. | 2001 Jan |
|
| Fluoride plus aluminum: useful tools in laboratory investigations, but messengers of false information. | 2002 |
|
| Bone cell mitogenic action of fluoroaluminate and aluminum fluoride but not that of sodium fluoride involves upregulation of the insulin-like growth factor system. | 2002 May |
|
| Parenteral nutrition-associated cholestasis in neonates: the role of aluminum. | 2003 Sep |
|
| [Pharmaceutical and pharmacological evaluation of Burow's solution (aluminum acetate solution), hospital preparation, and development of its rapid preparation method]. | 2004 Nov |
|
| Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. | 2005 Nov |
|
| Cytochrome-c oxidase inhibition in 26 aluminum phosphide poisoned patients. | 2006 |
|
| Aluminum and Alzheimer's disease, a personal perspective after 25 years. | 2006 |
|
| Some aspects of astroglial functions and aluminum implications for neurodegeneration. | 2006 Aug 30 |
|
| Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. | 2006 Nov |
|
| Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. | 2006 Nov |
|
| Aluminum and Alzheimer's disease: a new look. | 2006 Nov |
|
| The role of aluminum and copper on neuroinflammation and Alzheimer's disease. | 2006 Nov |
|
| Mechanisms of aluminum-induced neurodegeneration in animals: Implications for Alzheimer's disease. | 2006 Nov |
|
| Ototoxic effect of Burow solution applied to the guinea pig middle ear. | 2007 Aug |
|
| Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. | 2007 Oct |
|
| Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. | 2007 Oct |
|
| Ablative laser resurfacing: high-energy pulsed carbon dioxide and erbium:yttrium-aluminum-garnet. | 2007 Sep-Oct |
|
| Hyperglycemia in acute aluminum phosphide poisoning as a potential prognostic factor. | 2008 Jul |
|
| Retrospective analysis of 4-week inhalation studies in rats with focus on fate and pulmonary toxicity of two nanosized aluminum oxyhydroxides (boehmite) and pigment-grade iron oxide (magnetite): the key metric of dose is particle mass and not particle surface area. | 2009 May 17 |
|
| Altered glucose homeostasis in response to aluminium phosphide induced cellular oxygen deficit in rat. | 2010 Jul |
|
| Blood levels of methemoglobin in patients with aluminum phosphide poisoning and its correlation with patient's outcome. | 2011 Mar |
|
| Effect of acute aluminum phosphide exposure on rats: a biochemical and histological correlation. | 2012 Nov 23 |
|
| New insight into artifactual phenomena during in vitro toxicity assessment of engineered nanoparticles: study of TNF-α adsorption on alumina oxide nanoparticle. | 2013 Apr |
|
| Gene expression profile of mouse fibroblasts exposed to a biodegradable iron alloy for stents. | 2013 Nov |
|
| 1H NMR spectroscopic analysis detects metabolic disturbances in rat urine on acute exposure to heavy metal tungsten alloy based metals salt. | 2014 Mar 25 |
|
| Pesticide exposure and depression among male private pesticide applicators in the agricultural health study. | 2014 Sep |
|
| Molecular basis of carcinogenicity of tungsten alloy particles. | 2015 Mar 15 |
Sample Use Guides
DOMEBORO® SOOTHING SOAK
– dissolve 1 to 3 packets in a pint (16 oz) of cool or warm water
– stir until fully dissolved; do not strain or filter. The resulting mixture contains 0.16% (1 packet), 0.32% (2 packets), or 0.48% (3 packets) aluminum acetate and is ready for use
For use as a soak:
– soak affected area for 15 to 30 minutes as needed, or as directed by a doctor
– repeat 3 times a day or as directed by a doctor
– discard solution after each use.
For use as a compress or wet dressing:
– soak a clean, soft cloth in the solution.
– apply cloth loosely to affected area for 15 to 30 minutes
– repeat as needed or as directed by a doctor
– discard solution after each use
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EPA PESTICIDE CODE |
13906
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
||
|
CFR |
21 CFR 347.12
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C45678
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
3080712
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
C75770
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
DTXSID70170784
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
17621
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | RxNorm | ||
|
34S289N54E
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
C041524
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
ALUMINIUM SULFATE
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
74768
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
1017364
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
SUB11702MIG
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
17927-65-0
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
DB11239
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | |||
|
ALUMINUM SULFATE
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY | Description: Colourless, lustrous crystals or crystalline masses, or a white, crystalline powder; odourless. Solubility: Soluble in cold water; freely soluble in hot water; practically insoluble in ethanol (~750 g/l) TS. Category: Astringent drug; used in the preparation of aluminium acetate solution. Storage: Aluminium sulfate should be kept in a well-closed container.Aluminium sulfate contains a variable quantity of water of crystallization. Requirement: Aluminium sulfate contains not less than 51.0% and not more than the equivalent of 59.0% of Al2(SO4)3. | ||
|
34S289N54E
Created by
admin on Sat Dec 16 16:52:09 GMT 2023 , Edited by admin on Sat Dec 16 16:52:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
